Skip to content
eHealthTutorial — Research Peptide Reviews
Investigational oral small molecule • Not a peptide

Monoamine reuptake and obesity research

Tesofensine

Tesofensine is a non-peptide monoamine reuptake inhibitor studied in an obesity phase 2 trial. Oral trial findings are not evidence for a peptide reconstitution vial.

Explore the research
Generic research visual — not a commercial product
Compound typeNon-peptide small-molecule monoamine reuptake inhibitor
Evidence basePhase 2 randomized clinical study
Regulatory contextInvestigational / Not FDA-approved
Page purposeResearch overview
Why there is no compound calculator on this page

The trial investigated an oral small molecule, not a vial-based injectable peptide. A U-100 syringe chart would imply an unstudied product and route.

Research overview

What is Tesofensine?

Tesofensine inhibits reuptake of several monoamine neurotransmitters in experimental pharmacology. It is grouped with peptides by some supplier catalogs despite not being a peptide. It is not chemically or clinically interchangeable with GLP-1 agonists.

What has research examined?

A phase 2 randomized placebo-controlled study in 203 adults with obesity examined body weight, composition, and quality-of-life measures with studied oral tesofensine alongside dietary intervention. The study cannot certify a differently sourced material, route, or long-term risk profile.

Important limitation

Early trial outcomes do not establish an approved weight-management product or safe unsupervised use. No amount, preparation, or route is advised.

Research references

Calculation boundary

The trial investigated an oral small molecule, not a vial-based injectable peptide. A U-100 syringe chart would imply an unstudied product and route.

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.